NOT YET RECRUITING
NCT06929468
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer
The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck cancer. Researchers will compare patients who are receiving cisplatin chemoradiotherapy to patients who are only receiving radiotherapy. Patients will undergo standardized testing for hearing loss, tinnitus and vestibular dysfunction at baseline, during and after treatment. Optional genetic analyses will aim to identify genes known to predispose to cisplatin-induced ototoxicity.
Gender: All
Ages: 18 Years - 85 Years
Ototoxic Hearing Loss
Ototoxicity, Drug-Induced
Cisplatin-induced Hearing Loss
+8